{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:40:48Z","timestamp":1785775248931,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1908085 MH267"],"award-info":[{"award-number":["1908085 MH267"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It is widely acknowledged that nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus(T2DM) are all chronic metabolic diseases. The objective of this study is to retrospectively probe the association between the 25-hydroxyvitamin D (25-(OH)D) and NAFLD in type 2 diabetic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three hundred thirty-nine T2DM patients participated in this research and from November 2018 to September 2019 and were divided into simple T2DM group (108 cases) and T2DM with NAFLD group (231 cases) in conformity with abdominal ultrasound diagnosis. The NAFLD fibrosis score (NFS) \u22650.676 was defined as progressive liver fibrosis.231 T2DM with NAFLD patients were categorized into two subgroups: progressive liver fibrosis subgroup (48 cases) and without progressive liver fibrosis subgroup (183 cases).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence of NAFLD by Abdominal ultrasonography was 68%.The results indicated that the levels of 25-(OH) D were significantly lower in T2DM with NAFLD group than that in simple T2DM group(<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). The levels of 25-(OH) D were significantly lower in progressive liver fibrosis subgroup than that in patients without progressive liver fibrosis and simple T2DM,and 25-(OH) D levels were lower in without progressive liver fibrosis subgroup than that in simple T2DM group(<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01 or <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Multivariate logistic regression analysis showed that levels of 25-(OH) D were negative correlation with risk of NAFLD and progressive liver fibrosis(<jats:italic>p<\/jats:italic>\u2009=\u20090.011\u3001<jats:italic>p<\/jats:italic>\u2009=\u20090.044,respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>we could come to a conclusion that low levels of 25-(OH) D was a risk factor for NAFLD and progressive liver fibrosis in T2DM patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00762-1","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T11:02:38Z","timestamp":1621335758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuanyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqun","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"issue":"4","key":"762_CR1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643\u201354. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.014.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"762_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/hep.23521","volume":"51","author":"P Angulo","year":"2010","unstructured":"Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology. 2010;51(2):373\u20135. https:\/\/doi.org\/10.1002\/hep.23521.","journal-title":"Hepatology."},{"key":"762_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1136\/postgradmedj-2018-136316","volume":"95","author":"J Erica","year":"2019","unstructured":"Erica J, Janisha P, Eleonora S, Christopher D. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95:314\u201322.","journal-title":"Postgrad Med J"},{"issue":"1","key":"762_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease:meta-analytic assessment of prevalence,incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology."},{"issue":"4","key":"762_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2017.06.003.","journal-title":"J Hepatol"},{"issue":"4","key":"762_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.diabet.2019.11.004","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, et al. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 2020;46(4):296\u2013303. https:\/\/doi.org\/10.1016\/j.diabet.2019.11.004.","journal-title":"Diabetes Metab"},{"issue":"6","key":"762_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330\u201344. https:\/\/doi.org\/10.1038\/nrgastro.2013.41.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"762_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, et al. The NAFLD fibrosis score: a noninvasive system that identifies live fibrosis in patients with NAFLD. Hepatology. 2007;45:846\u201354.","journal-title":"Hepatology"},{"key":"762_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.metabol.2016.11.002","volume":"67","author":"EH Van den berg","year":"2017","unstructured":"Van den berg EH, Van Tienhoven-Wind LJ, Amini M, Schreuder TC, Faber KN, et al. Higher free triiodothyonine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the lifelines cohort study. Metabolism. 2017;67:62\u201371.","journal-title":"Metabolism"},{"key":"762_CR10","first-page":"191","volume":"3","author":"Y Dogan","year":"2015","unstructured":"Dogan Y, Sarli B, Baktir AO, Kurtul S, Akpek M, et al. 25-Hydroxy-vitamin D level may predict presence of coronary collaterals in patients with chronic coronary total occlusion. Postep Kardiol Inter. 2015;3:191\u20136.","journal-title":"Postep Kardiol Inter"},{"issue":"11","key":"762_CR11","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.3390\/nu12113302","volume":"12","author":"I Barchetta","year":"2020","unstructured":"Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): an update. Nutrients. 2020;12(11):3302\u201315. https:\/\/doi.org\/10.3390\/nu12113302.","journal-title":"Nutrients."},{"issue":"3","key":"762_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","volume":"153","author":"N Ding","year":"2013","unstructured":"Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, et al. A vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153(3):601\u201313. https:\/\/doi.org\/10.1016\/j.cell.2013.03.028.","journal-title":"Cell."},{"issue":"2","key":"762_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s12020-016-1152-x","volume":"55","author":"BB Yang","year":"2017","unstructured":"Yang BB, Chen YH, Zhang C, Shi CE, Hu KF, Zhou J, et al. Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease. Endocrine. 2017;55(2):582\u201390. https:\/\/doi.org\/10.1007\/s12020-016-1152-x.","journal-title":"Endocrine."},{"issue":"9","key":"762_CR14","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1007\/s11695-016-2070-y","volume":"26","author":"R Anty","year":"2016","unstructured":"Anty R, Hastier A, Canivet CM, Patouraux S, Schneck AS, Ferrari-Panaia P, et al. Severe vitamin D deficiency is not associated with liver damage in morbidly obese patients. Obes Surg. 2016;26(9):2138\u201343. https:\/\/doi.org\/10.1007\/s11695-016-2070-y.","journal-title":"Obes Surg"},{"issue":"1","key":"762_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4254\/wjh.v10.i1.142","volume":"10","author":"B Saberi","year":"2018","unstructured":"Saberi B, Dadabhai AS, Nanavati J, Wang L, Shinohara RT, Mullin GE. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: a PRISMA compliant systematic review and meta-analysis of pooled data. World J Hepatol. 2018;10(1):142\u201354. https:\/\/doi.org\/10.4254\/wjh.v10.i1.142.","journal-title":"World J Hepatol"},{"issue":"1","key":"762_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ecl.2013.09.010","volume":"43","author":"J Mitri","year":"2014","unstructured":"Mitri J, Pittas AG. Vitamin D and diabetes. Endocrinol Metab Clin N Am. 2014;43(1):205\u201332. https:\/\/doi.org\/10.1016\/j.ecl.2013.09.010.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"762_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jhep.2008.10.010","volume":"50","author":"JG Fan","year":"2009","unstructured":"Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J hepat. 2009;50:204\u201310.","journal-title":"J hepat"},{"key":"762_CR18","doi-asserted-by":"publisher","unstructured":"Tao Y, Gu HB, Wu JC, Sui J. Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects. Endocr Res. 2015;40:1\u20135. https:\/\/doi.org\/10.3109\/07435800.2014.952014.","DOI":"10.3109\/07435800.2014.952014"},{"key":"762_CR19","first-page":"419","volume":"29","author":"X Li","year":"2004","unstructured":"Li X, Zhou ZG, Qi HY, Chen XY, Huang G. Evaluation of insulin resistance and islet\u03b2cell function by using fasting C peptide instead of insulin to improve Homa formula. J Cent South Univ. 2004;29:419\u201323 (In Chinese).","journal-title":"J Cent South Univ"},{"issue":"3","key":"762_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.013.","journal-title":"J Hepatol"},{"issue":"2","key":"762_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41(2):372\u201382. https:\/\/doi.org\/10.2337\/dc17-1902.","journal-title":"Diabetes Care"},{"issue":"4","key":"762_CR22","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/hep.24737","volume":"55","author":"CL Roth","year":"2012","unstructured":"Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ. Etal. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012;55(4):1103\u201311. https:\/\/doi.org\/10.1002\/hep.24737.","journal-title":"Hepatology."},{"key":"762_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jhep.2010.11.028","volume":"55","author":"T Nakano","year":"2011","unstructured":"Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC. Etal. Impact of artificial sunlight therapy on the progressof non-alcoholic fatty liver disease in rats. J Hepatol. 2011;55:273\u20135.","journal-title":"J Hepatol"},{"key":"762_CR24","doi-asserted-by":"publisher","first-page":"168216","DOI":"10.1371\/journal.pone.0168216","volume":"11","author":"C Della Corte","year":"2016","unstructured":"Della Corte C, Carpino G, De Vito R, De Stefanis C, Alisi A, et al. Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: results from a single Centre trial. PLoS One. 2016;11:168216\u2013332.","journal-title":"PLoS One"},{"issue":"2","key":"762_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/1440-1681.12334","volume":"42","author":"ZG Lu","year":"2015","unstructured":"Lu ZG, Pan XP, Hu YQ, Hao YP, Luo YQ, Hu X, et al. Serum vitamin D levels are inversely related with non-alcoholic fatty liver disease independent of visceral obesity in Chinese postmenopausal women. Clin Exp Pharmacol Physiol. 2015;42(2):139\u201345. https:\/\/doi.org\/10.1111\/1440-1681.12334.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"762_CR26","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3748\/wjg.v24.i19.2073","volume":"24","author":"P Pierimarchi","year":"2018","unstructured":"Pierimarchi P. Role of osteoprotegerin\/receptor activator of nuclear factor kappa B\/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24:2073\u201382.","journal-title":"World J Gastroenterol"},{"key":"762_CR27","first-page":"1681","volume":"19","author":"JY Cai","year":"2020","unstructured":"Cai JY, Zhang ZY, Liu JQ, Xiao XL, Wang CZ. Et al. Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease. Exp Ther Med. 2020;19:1681\u20136.","journal-title":"Exp Ther Med"},{"key":"762_CR28","doi-asserted-by":"publisher","first-page":"117086","DOI":"10.1016\/j.lfs.2019.117086","volume":"245","author":"YY Liu","year":"2020","unstructured":"Liu YY, Wang MJ, Xu W, Zhang HM, Qian WH, et al. Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway. Life Sci. 2020;245:117086\u2013112.","journal-title":"Life Sci"},{"key":"762_CR29","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.dsx.2019.04.002","volume":"13","author":"SS Hosny","year":"2019","unstructured":"Hosny SS, Hm A, Mohammed WA, Ghannam HE. Study of relationship between total vitamin D level and NAFLD in a sample of Egyptian patients with and without T2DM. Diabetes Metab Syndr. 2019;13:1769\u201371.","journal-title":"Diabetes Metab Syndr"},{"key":"762_CR30","first-page":"19","volume":"99","author":"SJ Wang","year":"2020","unstructured":"Wang SJ, Cai BC, Han XK, Gao Y, Zhang XR, et al. Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus. Medicine. 2020;99:19\u201323.","journal-title":"Medicine."},{"key":"762_CR31","first-page":"117","volume":"28","author":"LH Yang","year":"2018","unstructured":"Yang LH, Liao X, Zhang H, Yang Y, Zhang SY, et al. Study on the relationship between liver fibrosis and serum 25-hydroxyvitamin D level in type 2 diabetes mellitus complicated with nonalcoholic fatty liver. Chin J Diabetes. 2018;28:117\u201322 (In Chinese).","journal-title":"Chin J Diabetes"},{"issue":"12","key":"762_CR32","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1074\/jbc.RA119.011487","volume":"295","author":"H Zhang","year":"2020","unstructured":"Zhang H, Shen Z, Lin YM, Zhang J, Zhang YW, et al. Vitamin D receptor targets hepatocyte nuclear factor 4\u03b1 and mediates protective effects of vitamin D in nonalcoholic fatty liver disease. J Biol Chem. 2020;295(12):3891\u2013905. https:\/\/doi.org\/10.1074\/jbc.RA119.011487.","journal-title":"J Biol Chem"},{"key":"762_CR33","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.11569\/wcjd.v20.i33.3191","volume":"20","author":"YF Li","year":"2012","unstructured":"Li YF, Tang XL, Ling WH. Inhibitory effect of 1,25- dihydroxyvitamin D3 on the process of liver fibrosis induced by nonalcoholic fatty liver in mice. World Chin J Digestol. 2012;20:3191\u20136 (In Chinese).","journal-title":"World Chin J Digestol"},{"key":"762_CR34","first-page":"32","volume":"50","author":"C Yu","year":"2019","unstructured":"Yu C, Chen L, Lin HM, Jiang YW, Wang LQ, et al. Relationship between serum 25- hydroxyvitamin D level and liver fibrosis risk in patients with nonalcoholic fatty liver disease. New Med. 2019;50:32\u20135 (In Chinese).","journal-title":"New Med"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00762-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00762-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00762-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T11:03:19Z","timestamp":1621335799000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00762-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00762-1","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine was passed and the informed consent was also signed in this study (2020MCZQ09).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}